Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin as Add-On to Metformin for 24 Weeks in Patients with Type 2 Diabetes

Trial Profile

Empagliflozin as Add-On to Metformin for 24 Weeks in Patients with Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2015 Results (pooled analysis of four, 24 week, phase III trials - NCT01159600, NCT01719003, NCT01778049, 3090558) presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
    • 23 Jul 2013 New trial record
    • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top